MEDICINE DETAILS
Vanflyta
Active ingredient: Quizartinib
Vanflyta is recorded in this directory with the active ingredient Quizartinib. This page brings together catalogue strength, dosage-form and pack records so they can be checked against a prescription.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Vanflyta used for?
VANFLYTA (Quizartinib) is a prescription medicine used to treat newly diagnosed acute myeloid leukemia (AML) with FLT3-ITD mutation.
Acute myeloid leukemia (AML) is an aggressive cancer affecting white blood cells. The FLT3-ITD mutation is commonly found in AML patients and can lead to a more rapid progression of the disease.
VANFLYTA is a targeted therapy that inhibits the FLT3-ITD mutation, thereby stopping or slowing the growth of cancer cells. The treatment is administered in combination with standard cytarabine and anthracycline induction chemotherapy, followed by cytarabine consolidation chemotherapy, and subsequently as maintenance monotherapy following consolidation chemotherapy.
Common side effects include low white blood cell counts, electrolyte imbalances (decreased levels of potassium, magnesium, or calcium), increased liver or muscle enzymes, diarrhea, mouth sores or redness (mucositis), nausea, abdominal pain, sepsis (serious infection throughout the body and organs), headache, vomiting, and upper respiratory tract infection.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Vanflyta identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
17.7 mg · 28 tablets Catalogue organisation: DAIICHI SANKYO DEUTSCHLAND GmbH
-
26.5 mg · 56 tablets Catalogue organisation: DAIICHI SANKYO DEUTSCHLAND GmbH
OFFICIAL SOURCES
Check the Vanflyta record at an official source.
Search for “Vanflyta” or “Quizartinib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Vanflyta.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Vanflyta
01What is Vanflyta?＋
This directory record associates the brand name Vanflyta with the active ingredient Quizartinib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Vanflyta strengths and packs are recorded?＋
The catalogue currently shows: 17.7 mg · 28 tablets; 26.5 mg · 56 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Vanflyta?＋
Catalogue records currently name: DAIICHI SANKYO DEUTSCHLAND GmbH. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Vanflyta?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Vanflyta, payment request, stock guarantee or binding offer.
06Can I buy Vanflyta from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.